JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 29, 2004; DOI: 10.1124/jpet.103.063347


0022-3565/04/3092-594-599$20.00
JPET 309:594-599, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.063347v1
309/2/594    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neuwelt, E. A.
Right arrow Articles by Muldoon, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neuwelt, E. A.
Right arrow Articles by Muldoon, L. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLCYSTEINE
Medline Plus Health Information
*Brain Cancer

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Bone Marrow Chemoprotection without Compromise of Chemotherapy Efficacy in a Rat Brain Tumor Model

Edward A. Neuwelt, Michael A. Pagel, Dale F. Kraemer, Darryl R. Peterson, and Leslie L. Muldoon

Departments of Neurology (E.A.N., L.L.M.) and Neurosurgery (E.A.N.), Division of Medical Informatics and Clinical Epidemiology (D.F.K.), and Department of Cell and Developmental Biology (L.L.M.), Oregon Health Sciences University, Portland, Oregon; Veterans Affairs Medical Center (E.A.N., M.A.P.), Portland, Oregon; and Departments of Physiology and Biophysics and Medicine (D.R.P.), Chicago Medical School, North Chicago, Illinois

Thiol chemoprotective agents can reduce chemotherapy side effects, but clinical use is limited due to concerns of impaired chemotherapeutic efficacy. We evaluated whether an optimized bone marrow chemoprotection regimen impaired the efficacy of enhanced chemotherapy against rat brain tumors. Nude rats with intracerebral human lung carcinoma xenografts were treated with carboplatin, melphalan, and etoposide phosphate delivered intra-arterially with osmotic blood-brain barrier disruption (n = 8/group). Thiol chemoprotection was N-acetyl-L-cysteine (1000 mg/kg) 60 min before chemotherapy and/or sodium thiosulfate (8 g/m2) 4 and 8 h after chemotherapy, when the blood-brain barrier is reestablished. Blood counts were obtained before treatment on day 3 and at sacrifice on day 9. N-acetylcysteine serum clearance half-life was 9 to 11 min. Pretreatment with N-acetylcysteine combined with delayed administration of sodium thiosulfate protected against toxicity toward total white cells, granulocytes, and platelets (P = 0.0016). Enhanced chemotherapy reduced intracerebral tumor volume to 4.3 ± 1.0 mm3 compared with 29.1 ± 4.1 mm3 in untreated animals (P < 0.0001). Tumor volume was 3.7 ± 0.6 mm3 in rats that received N-acetylcysteine before and sodium thiosulfate after chemotherapy. The data indicate the efficacy of enhanced chemotherapy for rat brain tumors was not affected by thiol chemoprotection that provided excellent protection for hematological toxicity. Negative interactions of thiols with antitumor efficacy were avoided by temporal and spatial separation of chemoprotectants and chemotherapy.


Received November 20, 2003; accepted January 28, 2004.

Address correspondence to: Dr. Edward A. Neuwelt, Oregon Health and Sciences University, L603, 3181 SW Sam Jackson Park Rd., Portland OR 97239. E-mail: neuwelte{at}ohsu.edu




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
M. E. Jung, J. W. Simpkins, A. M. Wilson, H. F. Downey, and R. T. Mallet
Intermittent hypoxia conditioning prevents behavioral deficit and brain oxidative stress in ethanol-withdrawn rats
J Appl Physiol, August 1, 2008; 105(2): 510 - 517.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. M. Harned, O. Kalous, A. Neuwelt, J. Loera, L. Ji, P. Iovine, R. Sposto, E. A. Neuwelt, and C. P. Reynolds
Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity
Clin. Cancer Res., January 15, 2008; 14(2): 533 - 540.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. L. Muldoon, C. Soussain, K. Jahnke, C. Johanson, T. Siegal, Q. R. Smith, W. A. Hall, K. Hynynen, P. D. Senter, D. M. Peereboom, et al.
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
J. Clin. Oncol., June 1, 2007; 25(16): 2295 - 2305.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J. H. Doroshow
Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity.
J Natl Cancer Inst, February 15, 2006; 98(4): 223 - 225.
[Full Text] [PDF]


Home page
JCOHome page
K. R. G. Knight, D. F. Kraemer, and E. A. Neuwelt
Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social Development
J. Clin. Oncol., December 1, 2005; 23(34): 8588 - 8596.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. T. Dickey, Y. J. Wu, L. L. Muldoon, and E. A. Neuwelt
Protection against Cisplatin-Induced Toxicities by N-Acetylcysteine and Sodium Thiosulfate as Assessed at the Molecular, Cellular, and in Vivo Levels
J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1052 - 1058.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. J. Wu, L. L. Muldoon, and E. A. Neuwelt
The Chemoprotective Agent N-Acetylcysteine Blocks Cisplatin-Induced Apoptosis through Caspase Signaling Pathway
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 424 - 431.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. D. Doolittle, L. E. Abrey, W. A. Bleyer, S. Brem, T. P. Davis, P. Dore-Duffy, L. R. Drewes, W. A. Hall, J. M. Hoffman, A. Korfel, et al.
New Frontiers in Translational Research in Neuro-oncology and the Blood-Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting
Clin. Cancer Res., January 15, 2005; 11(2): 421 - 428.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.